{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:31:01Z","timestamp":1768516261327,"version":"3.49.0"},"posted":{"date-parts":[[2024,12,11]]},"group-title":"Immunology","reference-count":86,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Two live attenuated vaccines (LAVs), LMA and LMP, were evaluated alone or in combination with a trivalent adenoviral vector-based vaccine (Ad5-YFV) for their efficacy and immune responses in wild type (WT) and interferon gamma (IFN\u03b3) knockout (KO) mice in a C57BL\/6 background. While LMA and LMP are triple deletion mutants of\n                  <jats:italic>Yersinia pestis<\/jats:italic>\n                  CO92 strain, Ad5-YFV incorporates three protective plague immunogens. An impressive 80-100% protection was observed in all vaccinated animals against highly lethal intranasal challenge doses of parental\n                  <jats:italic>Y. pestis<\/jats:italic>\n                  CO92. All vaccinated mice generated robust humoral and cellular immune responses. The immunized WT mice showed overall better antibody responses in both serum and bronchoalveolar lavage fluid with much higher percentages of polyfunctional T cell populations. On the other hand, vaccinated IFN\u03b3 KO mice displayed better B cell activity in germinal centers with higher percentages of activated antigen specific T cells and memory T cells. In addition, depletion of IFN\u03b3 and tumor necrosis factor alpha (TNF\u03b1) from immunized WT mice prior to and during infection did not reduce protection against pulmonary\n                  <jats:italic>Y. pestis<\/jats:italic>\n                  CO92 challenge. These data demonstrated a dispensable nature of IFN\u03b3 in mediating protection by the aforementioned vaccines. This is the first detailed immunogenicity study of two plague LAVs administered either alone or in combination with an Ad5-YFV vaccine in a prime-boost immunization strategy in IFN\u03b3 KO mice. Further, by combining advantages of live-attenuated and adenovirus-based vaccines, augmentation of generalized immune responses were observed which could be beneficial in providing long-lasting immunity in the host.\n                <\/jats:p>","DOI":"10.1101\/2024.12.06.627261","type":"posted-content","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T22:57:17Z","timestamp":1734044237000},"source":"Crossref","is-referenced-by-count":0,"title":["Combination of live attenuated and adenovirus-based vaccines completely protects interferon gamma (IFN\u03b3) knockout mice against pneumonic plague"],"prefix":"10.64898","author":[{"given":"Emily K.","family":"Hendrix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Kilgore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blake H.","family":"Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok K.","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024121223350930000_2024.12.06.627261v1.1","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.10.1.35"},{"key":"2024121223350930000_2024.12.06.627261v1.2","first-page":"4","article-title":"Weekly Bulletin on Outbreaks and Other Emergencies","volume":"50","author":"World Health Organization Africa","year":"2017","journal-title":"Week"},{"key":"2024121223350930000_2024.12.06.627261v1.3","unstructured":"World Health Organization, Plague Key Facts Fact Sheets (2022)."},{"key":"2024121223350930000_2024.12.06.627261v1.4","unstructured":"World Health Organization, Facts About PlagueNewsroom (2022) (available at https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/plague)."},{"key":"2024121223350930000_2024.12.06.627261v1.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-021-11389-6"},{"key":"2024121223350930000_2024.12.06.627261v1.6","doi-asserted-by":"publisher","DOI":"10.24171\/j.phrp.2021.0288"},{"key":"2024121223350930000_2024.12.06.627261v1.7","unstructured":"A. G. C. DynPort Vaccine Company LLC, Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V (2006), doi:NCT00097396."},{"key":"2024121223350930000_2024.12.06.627261v1.8","unstructured":"A. G. C. DynPort Vaccine Company LLC, Recombinant Plague Vaccine rF1V in Healthy VolunteersClinicalTrials.gov (2008), doi:NCT00332956."},{"key":"2024121223350930000_2024.12.06.627261v1.9","unstructured":"A. G. C. DynPort Vaccine Company LLC, Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without AdjuvantClinicalTrials.gov (2012), doi:NCT01122784."},{"key":"2024121223350930000_2024.12.06.627261v1.10","unstructured":"PharmAthene UK Limited, One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)ClinicalTrials.gov (2007), doi:NCT00246467."},{"key":"2024121223350930000_2024.12.06.627261v1.11","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID), Dose Escalation Trial of a Plague Vaccine, Flagellin\/F1\/V, in Healthy Adult VolunteersClinicalTrials.gov (2014), doi:NCT01381744."},{"key":"2024121223350930000_2024.12.06.627261v1.12","unstructured":"Jiangsu Province Centers for Disease Control and Prevention, Immunogenicity and Safety of Subunit Plague VaccineClinicalTrials.gov (2015), doi:NCT02596308."},{"key":"2024121223350930000_2024.12.06.627261v1.13","unstructured":"Jiangsu Province Centers for Disease Control and Prevention, Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization RegimensClinicalTrials.gov (2022), doi:NCT05330624."},{"key":"2024121223350930000_2024.12.06.627261v1.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218366"},{"key":"2024121223350930000_2024.12.06.627261v1.15","unstructured":"Oxford Vaccine Group, Investigating a Vaccine Against Plague (PlaVac)Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) , 1\u201321 (2021)."},{"key":"2024121223350930000_2024.12.06.627261v1.16","unstructured":"Jiangsu Province Centers for Disease Control and Prevention, Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimen ClinicalTrials.gov (2022), doi:NCT05330624."},{"key":"2024121223350930000_2024.12.06.627261v1.17","unstructured":"Dynavax Technologies Corporation, Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018\u00ae Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age ClinicalTrials.gov (2024), doi:NCT05506969."},{"key":"2024121223350930000_2024.12.06.627261v1.18","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00064-11"},{"key":"2024121223350930000_2024.12.06.627261v1.19","unstructured":"T. V. Meka-Mechenko , in Advances in Experimental Medicine and Biology, (2003), vol. 529."},{"key":"2024121223350930000_2024.12.06.627261v1.20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01830"},{"key":"2024121223350930000_2024.12.06.627261v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00090-N"},{"key":"2024121223350930000_2024.12.06.627261v1.22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.013"},{"key":"2024121223350930000_2024.12.06.627261v1.23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis433"},{"key":"2024121223350930000_2024.12.06.627261v1.24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc1010939"},{"key":"2024121223350930000_2024.12.06.627261v1.25","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.6.965"},{"key":"2024121223350930000_2024.12.06.627261v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.20"},{"key":"2024121223350930000_2024.12.06.627261v1.27","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00499-15"},{"key":"2024121223350930000_2024.12.06.627261v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2012.09.011"},{"key":"2024121223350930000_2024.12.06.627261v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2015.02.005"},{"key":"2024121223350930000_2024.12.06.627261v1.30","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02778-14"},{"key":"2024121223350930000_2024.12.06.627261v1.31","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03223-21"},{"key":"2024121223350930000_2024.12.06.627261v1.32","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00150-16"},{"key":"2024121223350930000_2024.12.06.627261v1.33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-5-38"},{"key":"2024121223350930000_2024.12.06.627261v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2005.02.016"},{"key":"2024121223350930000_2024.12.06.627261v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00275-3"},{"key":"2024121223350930000_2024.12.06.627261v1.36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210115"},{"key":"2024121223350930000_2024.12.06.627261v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90163-9"},{"key":"2024121223350930000_2024.12.06.627261v1.38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.323"},{"key":"2024121223350930000_2024.12.06.627261v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2004.06.009"},{"key":"2024121223350930000_2024.12.06.627261v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.063"},{"key":"2024121223350930000_2024.12.06.627261v1.41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI135460"},{"key":"2024121223350930000_2024.12.06.627261v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70050-8"},{"key":"2024121223350930000_2024.12.06.627261v1.43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506840102"},{"key":"2024121223350930000_2024.12.06.627261v1.44","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/745483"},{"key":"2024121223350930000_2024.12.06.627261v1.45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4461"},{"key":"2024121223350930000_2024.12.06.627261v1.46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003303"},{"key":"2024121223350930000_2024.12.06.627261v1.47","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12929"},{"key":"2024121223350930000_2024.12.06.627261v1.48","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00749-16"},{"key":"2024121223350930000_2024.12.06.627261v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(99)80067-3"},{"key":"2024121223350930000_2024.12.06.627261v1.50","doi-asserted-by":"publisher","DOI":"10.1126\/science.8456301"},{"key":"2024121223350930000_2024.12.06.627261v1.51","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018507"},{"key":"2024121223350930000_2024.12.06.627261v1.52","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2000.00955.x"},{"key":"2024121223350930000_2024.12.06.627261v1.53","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00185-06"},{"key":"2024121223350930000_2024.12.06.627261v1.54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207587"},{"key":"2024121223350930000_2024.12.06.627261v1.55","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.5.2644-2654.2005"},{"key":"2024121223350930000_2024.12.06.627261v1.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2014.10.012"},{"key":"2024121223350930000_2024.12.06.627261v1.57","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.13.4.7546779"},{"key":"2024121223350930000_2024.12.06.627261v1.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.11.032"},{"key":"2024121223350930000_2024.12.06.627261v1.59","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.00228801"},{"key":"2024121223350930000_2024.12.06.627261v1.60","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00408-20"},{"key":"2024121223350930000_2024.12.06.627261v1.61","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20173"},{"key":"2024121223350930000_2024.12.06.627261v1.62","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00408-13"},{"key":"2024121223350930000_2024.12.06.627261v1.63","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00296-19"},{"key":"2024121223350930000_2024.12.06.627261v1.64","doi-asserted-by":"publisher","DOI":"10.3390\/v10050237"},{"key":"2024121223350930000_2024.12.06.627261v1.65","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1997.56.471"},{"key":"2024121223350930000_2024.12.06.627261v1.66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1017385"},{"key":"2024121223350930000_2024.12.06.627261v1.67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2012.01124.x"},{"key":"2024121223350930000_2024.12.06.627261v1.68","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.001001"},{"key":"2024121223350930000_2024.12.06.627261v1.69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02469"},{"key":"2024121223350930000_2024.12.06.627261v1.70","doi-asserted-by":"publisher","DOI":"10.1038\/nri3804"},{"key":"2024121223350930000_2024.12.06.627261v1.71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010671"},{"key":"2024121223350930000_2024.12.06.627261v1.72","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20032014"},{"key":"2024121223350930000_2024.12.06.627261v1.73","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.003223"},{"key":"2024121223350930000_2024.12.06.627261v1.74","doi-asserted-by":"publisher","DOI":"10.1038\/382174a0"},{"key":"2024121223350930000_2024.12.06.627261v1.75","doi-asserted-by":"publisher","DOI":"10.1038\/380630a0"},{"key":"2024121223350930000_2024.12.06.627261v1.76","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.2.165"},{"key":"2024121223350930000_2024.12.06.627261v1.77","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1367"},{"key":"2024121223350930000_2024.12.06.627261v1.78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.26.12932"},{"key":"2024121223350930000_2024.12.06.627261v1.79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.143.1.266"},{"key":"2024121223350930000_2024.12.06.627261v1.80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.3.961"},{"key":"2024121223350930000_2024.12.06.627261v1.81","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02719.x"},{"key":"2024121223350930000_2024.12.06.627261v1.82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05133.x"},{"key":"2024121223350930000_2024.12.06.627261v1.83","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines6030050"},{"key":"2024121223350930000_2024.12.06.627261v1.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.06.018"},{"key":"2024121223350930000_2024.12.06.627261v1.85","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05180-11"},{"key":"2024121223350930000_2024.12.06.627261v1.86","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402058"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.12.06.627261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:38:55Z","timestamp":1768462735000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.12.06.627261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":86,"URL":"https:\/\/doi.org\/10.1101\/2024.12.06.627261","relation":{},"subject":[],"published":{"date-parts":[[2024,12,11]]},"subtype":"preprint"}}